OA11236A - Azetidinylpropylpiperidine derivatives intermediates and use as tachykinin antagonists - Google Patents

Azetidinylpropylpiperidine derivatives intermediates and use as tachykinin antagonists Download PDF

Info

Publication number: OA11236A
Authority: OA; OAPI
Prior art keywords: halogen; optionally substituted; compound; alkyl; disease
Prior art date: 1997-07-04

Application number

OA9900282A

Other languages

English (en)

Inventor

David Alker

Thomas Victor Magee

Graham Nigel Maw

Donald Stuart Middleton

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-04

Filing date

1999-12-15

Publication date

2003-05-27

1999-12-15 Application filed by Pfizer filed Critical Pfizer

2003-05-27 Publication of OA11236A publication Critical patent/OA11236A/en

Links

102000003141 Tachykinin Human genes 0.000 title claims abstract description 9
108060008037 tachykinin Proteins 0.000 title claims abstract description 9
239000005557 antagonist Substances 0.000 title claims description 8
239000000543 intermediate Substances 0.000 title description 8
IHOZTRFPYRXIIN-UHFFFAOYSA-N 1-[3-(azetidin-1-yl)propyl]piperidine Chemical class C1CCCCN1CCCN1CCC1 IHOZTRFPYRXIIN-UHFFFAOYSA-N 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 164
229910052736 halogen Inorganic materials 0.000 claims abstract description 98
150000002367 halogens Chemical class 0.000 claims abstract description 96
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 35
125000001424 substituent group Chemical group 0.000 claims abstract description 25
150000003839 salts Chemical class 0.000 claims abstract description 24
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 22
125000003118 aryl group Chemical group 0.000 claims abstract description 12
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 7
108010040722 Neurokinin-2 Receptors Proteins 0.000 claims abstract description 7
102100029409 Neuromedin-K receptor Human genes 0.000 claims abstract description 7
101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 claims abstract description 6
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims abstract description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
102100037342 Substance-K receptor Human genes 0.000 claims abstract description 4
125000000217 alkyl group Chemical group 0.000 claims description 96
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 84
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 59
239000000203 mixture Substances 0.000 claims description 55
238000000034 method Methods 0.000 claims description 47
208000035475 disorder Diseases 0.000 claims description 45
201000010099 disease Diseases 0.000 claims description 39
238000006243 chemical reaction Methods 0.000 claims description 31
125000000753 cycloalkyl group Chemical group 0.000 claims description 30
125000003545 alkoxy group Chemical group 0.000 claims description 20
238000010992 reflux Methods 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 15
201000004624 Dermatitis Diseases 0.000 claims description 14
206010020751 Hypersensitivity Diseases 0.000 claims description 12
229910003844 NSO2 Inorganic materials 0.000 claims description 12
208000002193 Pain Diseases 0.000 claims description 12
208000026935 allergic disease Diseases 0.000 claims description 12
210000003169 central nervous system Anatomy 0.000 claims description 12
230000002496 gastric effect Effects 0.000 claims description 12
208000004296 neuralgia Diseases 0.000 claims description 12
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 7
-1 3,4-difluorophenyl Chemical group 0.000 claims description 6
208000024827 Alzheimer disease Diseases 0.000 claims description 6
208000001387 Causalgia Diseases 0.000 claims description 6
208000000094 Chronic Pain Diseases 0.000 claims description 6
206010009900 Colitis ulcerative Diseases 0.000 claims description 6
208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 6
206010010741 Conjunctivitis Diseases 0.000 claims description 6
206010012289 Dementia Diseases 0.000 claims description 6
206010012442 Dermatitis contact Diseases 0.000 claims description 6
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
206010021639 Incontinence Diseases 0.000 claims description 6
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 6
208000028017 Psychotic disease Diseases 0.000 claims description 6
201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
208000005298 acute pain Diseases 0.000 claims description 6
230000007815 allergy Effects 0.000 claims description 6
208000006673 asthma Diseases 0.000 claims description 6
208000010668 atopic eczema Diseases 0.000 claims description 6
208000029162 bladder disease Diseases 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 6
206010009887 colitis Diseases 0.000 claims description 6
208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 6
208000010247 contact dermatitis Diseases 0.000 claims description 6
201000003146 cystitis Diseases 0.000 claims description 6
201000006549 dyspepsia Diseases 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
230000009610 hypersensitivity Effects 0.000 claims description 6
208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
201000006417 multiple sclerosis Diseases 0.000 claims description 6
208000033808 peripheral neuropathy Diseases 0.000 claims description 6
206010039083 rhinitis Diseases 0.000 claims description 6
208000026533 urinary bladder disease Diseases 0.000 claims description 6
208000000187 Abnormal Reflex Diseases 0.000 claims description 5
208000007848 Alcoholism Diseases 0.000 claims description 5
206010002383 Angina Pectoris Diseases 0.000 claims description 5
206010011224 Cough Diseases 0.000 claims description 5
208000011231 Crohn disease Diseases 0.000 claims description 5
206010012335 Dependence Diseases 0.000 claims description 5
208000034347 Faecal incontinence Diseases 0.000 claims description 5
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
208000019695 Migraine disease Diseases 0.000 claims description 5
208000018737 Parkinson disease Diseases 0.000 claims description 5
208000017442 Retinal disease Diseases 0.000 claims description 5
206010038923 Retinopathy Diseases 0.000 claims description 5
208000025747 Rheumatic disease Diseases 0.000 claims description 5
241000159243 Toxicodendron radicans Species 0.000 claims description 5
108010046334 Urease Proteins 0.000 claims description 5
208000024780 Urticaria Diseases 0.000 claims description 5
206010047700 Vomiting Diseases 0.000 claims description 5
201000007930 alcohol dependence Diseases 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 5
208000006275 fascioliasis Diseases 0.000 claims description 5
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
206010020745 hyperreflexia Diseases 0.000 claims description 5
230000035859 hyperreflexia Effects 0.000 claims description 5
201000001881 impotence Diseases 0.000 claims description 5
206010022000 influenza Diseases 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
206010027599 migraine Diseases 0.000 claims description 5
208000005877 painful neuropathy Diseases 0.000 claims description 5
102000005962 receptors Human genes 0.000 claims description 5
108020003175 receptors Proteins 0.000 claims description 5
230000001629 suppression Effects 0.000 claims description 5
230000002889 sympathetic effect Effects 0.000 claims description 5
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
230000002455 vasospastic effect Effects 0.000 claims description 5
208000019901 Anxiety disease Diseases 0.000 claims description 4
241000894006 Bacteria Species 0.000 claims description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 4
208000019693 Lung disease Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
206010039710 Scleroderma Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
230000003612 virological effect Effects 0.000 claims description 4
206010003645 Atopy Diseases 0.000 claims description 3
208000027932 Collagen disease Diseases 0.000 claims description 3
208000001640 Fibromyalgia Diseases 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
210000002950 fibroblast Anatomy 0.000 claims description 3
239000011737 fluorine Substances 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
230000002981 neuropathic effect Effects 0.000 claims description 3
230000000392 somatic effect Effects 0.000 claims description 3
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
102000008186 Collagen Human genes 0.000 claims description 2
108010035532 Collagen Proteins 0.000 claims description 2
208000027771 Obstructive airways disease Diseases 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
229920001436 collagen Polymers 0.000 claims description 2
125000004188 dichlorophenyl group Chemical group 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 9
125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 2
JYQQWQJCEUMXQZ-UHFFFAOYSA-N methyl cyanate Chemical compound COC#N JYQQWQJCEUMXQZ-UHFFFAOYSA-N 0.000 claims 2
ICQSKAQXLPIUOE-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1CNCCC1 ICQSKAQXLPIUOE-UHFFFAOYSA-N 0.000 claims 1
YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 claims 1
108010040716 Neurokinin-3 Receptors Proteins 0.000 claims 1
239000002671 adjuvant Substances 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
238000006268 reductive amination reaction Methods 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 220
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 175
238000002360 preparation method Methods 0.000 description 54
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
239000000243 solution Substances 0.000 description 51
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
238000005481 NMR spectroscopy Methods 0.000 description 34
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 29
239000000908 ammonium hydroxide Substances 0.000 description 29
235000011114 ammonium hydroxide Nutrition 0.000 description 29
229940043379 ammonium hydroxide Drugs 0.000 description 29
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
238000004809 thin layer chromatography Methods 0.000 description 25
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
239000011541 reaction mixture Substances 0.000 description 19
239000012267 brine Substances 0.000 description 18
235000019439 ethyl acetate Nutrition 0.000 description 17
229940093499 ethyl acetate Drugs 0.000 description 17
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 15
239000000741 silica gel Substances 0.000 description 15
229910002027 silica gel Inorganic materials 0.000 description 15
229910021653 sulphate ion Inorganic materials 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000460 chlorine Substances 0.000 description 12
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
239000002904 solvent Substances 0.000 description 12
238000001914 filtration Methods 0.000 description 11
239000006260 foam Substances 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
238000004587 chromatography analysis Methods 0.000 description 9
238000004440 column chromatography Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
238000000746 purification Methods 0.000 description 9
239000000126 substance Substances 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000012044 organic layer Substances 0.000 description 8
229910052938 sodium sulfate Inorganic materials 0.000 description 8
235000011152 sodium sulphate Nutrition 0.000 description 8
239000007787 solid Substances 0.000 description 8
102400000097 Neurokinin A Human genes 0.000 description 7
101800000399 Neurokinin A Proteins 0.000 description 7
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 7
238000007796 conventional method Methods 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 7
238000012360 testing method Methods 0.000 description 7
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 6
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 6
102100024304 Protachykinin-1 Human genes 0.000 description 6
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 6
229910052794 bromium Inorganic materials 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000001816 cooling Methods 0.000 description 6
239000012043 crude product Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
229910000027 potassium carbonate Inorganic materials 0.000 description 6
229940093956 potassium carbonate Drugs 0.000 description 6
235000011181 potassium carbonates Nutrition 0.000 description 6
238000010898 silica gel chromatography Methods 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
230000006978 adaptation Effects 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
229960001407 sodium bicarbonate Drugs 0.000 description 5
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
102000046798 Neurokinin B Human genes 0.000 description 3
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 3
102000019299 Neurokinin NK3 receptors Human genes 0.000 description 3
108050006653 Neurokinin NK3 receptors Proteins 0.000 description 3
101800002813 Neurokinin-B Proteins 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
239000013058 crude material Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
201000001119 neuropathy Diseases 0.000 description 3
230000007823 neuropathy Effects 0.000 description 3
235000015497 potassium bicarbonate Nutrition 0.000 description 3
229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
239000011736 potassium bicarbonate Substances 0.000 description 3
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
229940086066 potassium hydrogencarbonate Drugs 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000010791 quenching Methods 0.000 description 3
230000000171 quenching effect Effects 0.000 description 3
239000002002 slurry Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000010189 synthetic method Methods 0.000 description 3
MSVZMUILYMLJCF-UHFFFAOYSA-N (1-benzhydrylazetidin-3-yl) methanesulfonate Chemical compound C1C(OS(=O)(=O)C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 MSVZMUILYMLJCF-UHFFFAOYSA-N 0.000 description 2
HMHYXLVEFVGOPM-QKUYTOGTSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutan Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C1=CC=CC=C1 HMHYXLVEFVGOPM-QKUYTOGTSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
KTTHNJILQSHJHQ-UHFFFAOYSA-N 4-(azetidin-3-yl)morpholine;dihydrochloride Chemical compound Cl.Cl.C1NCC1N1CCOCC1 KTTHNJILQSHJHQ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
101000600912 Homo sapiens Substance-K receptor Proteins 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
229910000024 caesium carbonate Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
230000001595 contractor effect Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
239000000018 receptor agonist Substances 0.000 description 2
229940044601 receptor agonist Drugs 0.000 description 2
108010016070 senktide Proteins 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000007858 starting material Substances 0.000 description 2
ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000003039 volatile agent Substances 0.000 description 2
RTCUCQWIICFPOD-VIFPVBQESA-N (1s)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-VIFPVBQESA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
FUJSJWRORKKPAI-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Cl)C=C1Cl FUJSJWRORKKPAI-UHFFFAOYSA-N 0.000 description 1
QWZNCAFWRZZJMA-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1Cl QWZNCAFWRZZJMA-UHFFFAOYSA-N 0.000 description 1
KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 1
DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
OZYYQTRHHXLTKX-UHFFFAOYSA-N 7-octenoic acid Chemical compound OC(=O)CCCCCC=C OZYYQTRHHXLTKX-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010410 dusting Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006210 lotion Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
SVDVKEBISAOWJT-UHFFFAOYSA-N n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1 SVDVKEBISAOWJT-UHFFFAOYSA-N 0.000 description 1
LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
238000005897 peptide coupling reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Oncology (AREA)
Virology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA9900282A 1997-07-04 1999-12-15 Azetidinylpropylpiperidine derivatives intermediates and use as tachykinin antagonists OA11236A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9714129.5A GB9714129D0 (en)	1997-07-04	1997-07-04	Azetidines

Publications (1)

Publication Number	Publication Date
OA11236A true OA11236A (en)	2003-05-27

Family

ID=10815370

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900282A OA11236A (en)	1997-07-04	1999-12-15	Azetidinylpropylpiperidine derivatives intermediates and use as tachykinin antagonists

Country Status (36)

Country	Link
US (1)	US6262046B1 (is)
EP (1)	EP1023285A1 (is)
JP (1)	JP2000511207A (is)
KR (1)	KR20010015532A (is)
CN (1)	CN1261887A (is)
AP (1)	AP1110A (is)
AR (1)	AR013171A1 (is)
AU (1)	AU726708B2 (is)
BG (1)	BG103992A (is)
BR (1)	BR9810544A (is)
CA (1)	CA2294193A1 (is)
CO (1)	CO4950604A1 (is)
DZ (1)	DZ2550A1 (is)
EA (1)	EA002773B1 (is)
GB (1)	GB9714129D0 (is)
GT (1)	GT199800106A (is)
HN (1)	HN1998003689A (is)
HR (1)	HRP20000002B1 (is)
HU (1)	HUP0002330A3 (is)
ID (1)	ID24090A (is)
IL (1)	IL133433A0 (is)
IS (1)	IS5295A (is)
MA (1)	MA26519A1 (is)
NO (1)	NO996115L (is)
NZ (1)	NZ501715A (is)
OA (1)	OA11236A (is)
PA (1)	PA8454601A1 (is)
PE (1)	PE83999A1 (is)
PL (1)	PL338004A1 (is)
SK (1)	SK182799A3 (is)
TN (1)	TNSN98127A1 (is)
TR (1)	TR200000025T2 (is)
TW (1)	TW492960B (is)
UY (1)	UY25079A1 (is)
WO (1)	WO1999001451A1 (is)
ZA (1)	ZA985875B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9714129D0 (en)	1997-07-04	1997-09-10	Pfizer Ltd	Azetidines
AU1089599A (en) *	1997-10-15	1999-05-03	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
FR2787449B3 (fr)	1998-12-15	2001-01-12	Sanofi Sa	Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation
FR2787448B3 (fr) *	1998-12-18	2001-01-12	Sanofi Sa	Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation
FR2805810B1 (fr) *	2000-03-03	2002-04-26	Aventis Pharma Sa	Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) *	2000-03-03	2002-04-26	Aventis Pharma Sa	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
US6566356B2 (en)	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
ES2282731T3 (es) *	2002-12-23	2007-10-16	Janssen Pharmaceutica N.V.	Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas.
TW200508221A (en)	2003-06-13	2005-03-01	Astrazeneca Ab	New azetidine compounds
TW200630337A (en)	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
FR2876689B1 (fr) *	2004-10-14	2008-02-22	Aventis Pharma Sa	Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
WO2006094948A1 (en) *	2005-03-08	2006-09-14	Janssen Pharmaceutica N.V.	Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
WO2007110449A1 (en) *	2006-03-29	2007-10-04	Euro-Celtique S.A.	Benzenesulfonamide compounds and their use
TW200812963A (en) *	2006-04-13	2008-03-16	Euro Celtique Sa	Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) *	2006-04-13	2007-10-25	Euro-Celtique S.A.	Benzenesulfonamide compounds and their use as blockers of calcium channels
US8106208B2 (en)	2006-05-18	2012-01-31	Albireo Ab	Benzamide compounds that act as NK receptor antagonists
JP2010516734A (ja)	2007-01-24	2010-05-20	グラクソグループリミテッド	３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
US8399486B2 (en)	2007-04-09	2013-03-19	Purdue Pharma L.P.	Benzenesulfonyl compounds and the use thereof
CN101778837A (zh) *	2007-08-07	2010-07-14	弗·哈夫曼-拉罗切有限公司	作为nk3受体拮抗剂的吡咯烷芳基-醚
US8765736B2 (en) *	2007-09-28	2014-07-01	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
KR102559211B1 (ko)	2015-06-23	2023-07-25	에자이 알앤드디 매니지먼트 가부시키가이샤	(6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
BR112019023064A2 (pt)	2017-05-16	2020-06-09	Eisai R&D Man Co Ltd	tratamento de carcinoma hepatocelular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625060A (en)	1991-05-03	1997-04-29	Elf Sanofi	Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present
FR2676055B1 (fr) *	1991-05-03	1993-09-03	Sanofi Elf	Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW432061B (en) *	1994-08-09	2001-05-01	Pfizer Res & Dev	Lactams
FR2729951B1 (fr)	1995-01-30	1997-04-18	Sanofi Sa	Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
GB9600235D0 (en)	1996-01-05	1996-03-06	Pfizer Ltd	Therapeutic agents
GB9601697D0 (en) *	1996-01-27	1996-03-27	Pfizer Ltd	Therapeutic agents
GB9714129D0 (en)	1997-07-04	1997-09-10	Pfizer Ltd	Azetidines

1997
- 1997-07-04 GB GBGB9714129.5A patent/GB9714129D0/en active Pending
1998
- 1998-06-01 TW TW087108533A patent/TW492960B/zh active
- 1998-06-30 HN HN1998003689A patent/HN1998003689A/es unknown
- 1998-07-01 ID IDW20000006A patent/ID24090A/id unknown
- 1998-07-01 CN CN98806898A patent/CN1261887A/zh active Pending
- 1998-07-01 HR HR970497A patent/HRP20000002B1/xx not_active IP Right Cessation
- 1998-07-01 MA MA25151A patent/MA26519A1/fr unknown
- 1998-07-01 HU HU0002330A patent/HUP0002330A3/hu unknown
- 1998-07-01 AU AU88062/98A patent/AU726708B2/en not_active Ceased
- 1998-07-01 SK SK1827-99A patent/SK182799A3/sk unknown
- 1998-07-01 TR TR2000/00025T patent/TR200000025T2/xx unknown
- 1998-07-01 CA CA002294193A patent/CA2294193A1/en not_active Abandoned
- 1998-07-01 PL PL98338004A patent/PL338004A1/xx unknown
- 1998-07-01 EA EA199901102A patent/EA002773B1/ru not_active IP Right Cessation
- 1998-07-01 US US09/423,771 patent/US6262046B1/en not_active Expired - Fee Related
- 1998-07-01 BR BR9810544-2A patent/BR9810544A/pt not_active IP Right Cessation
- 1998-07-01 IL IL13343398A patent/IL133433A0/xx unknown
- 1998-07-01 DZ DZ980160A patent/DZ2550A1/xx active
- 1998-07-01 KR KR1020007000013A patent/KR20010015532A/ko not_active Abandoned
- 1998-07-01 JP JP11506382A patent/JP2000511207A/ja active Pending
- 1998-07-01 UY UY25079A patent/UY25079A1/es not_active IP Right Cessation
- 1998-07-01 NZ NZ501715A patent/NZ501715A/en unknown
- 1998-07-01 PE PE1998000589A patent/PE83999A1/es not_active Application Discontinuation
- 1998-07-01 WO PCT/EP1998/004177 patent/WO1999001451A1/en not_active Ceased
- 1998-07-01 EP EP98939619A patent/EP1023285A1/en not_active Withdrawn
- 1998-07-02 AR ARP980103228A patent/AR013171A1/es not_active Application Discontinuation
- 1998-07-02 PA PA19988454601A patent/PA8454601A1/es unknown
- 1998-07-02 AP APAP/P/1998/001291A patent/AP1110A/en active
- 1998-07-03 ZA ZA9805875A patent/ZA985875B/xx unknown
- 1998-07-03 CO CO98037815A patent/CO4950604A1/es unknown
- 1998-07-10 TN TNTNSN98127A patent/TNSN98127A1/fr unknown
- 1998-07-14 GT GT199800106A patent/GT199800106A/es unknown
1999
- 1999-12-10 NO NO996115A patent/NO996115L/no not_active Application Discontinuation
- 1999-12-10 IS IS5295A patent/IS5295A/is unknown
- 1999-12-13 BG BG103992A patent/BG103992A/xx unknown
- 1999-12-15 OA OA9900282A patent/OA11236A/en unknown

Also Published As

Publication number	Publication date
CO4950604A1 (es)	2000-09-01
IL133433A0 (en)	2001-04-30
HUP0002330A3 (en)	2002-05-28
WO1999001451A1 (en)	1999-01-14
JP2000511207A (ja)	2000-08-29
IS5295A (is)	1999-12-10
GB9714129D0 (en)	1997-09-10
NO996115L (no)	2000-02-22
EA199901102A1 (ru)	2000-08-28
DZ2550A1 (fr)	2003-02-08
AP1110A (en)	2002-10-10
KR20010015532A (ko)	2001-02-26
HUP0002330A2 (hu)	2001-06-28
AU726708B2 (en)	2000-11-16
AU8806298A (en)	1999-01-25
EP1023285A1 (en)	2000-08-02
PA8454601A1 (es)	2000-05-24
ZA985875B (en)	2000-01-10
HRP20000002B1 (en)	2002-06-30
CN1261887A (zh)	2000-08-02
HRP20000002A2 (en)	2000-12-31
TR200000025T2 (tr)	2000-06-21
SK182799A3 (en)	2001-11-06
EA002773B1 (ru)	2002-08-29
HN1998003689A (es)	1999-01-08
PE83999A1 (es)	1999-09-11
NZ501715A (en)	2001-06-29
AR013171A1 (es)	2000-12-13
US6262046B1 (en)	2001-07-17
PL338004A1 (en)	2000-09-25
ID24090A (id)	2000-07-06
NO996115D0 (no)	1999-12-10
GT199800106A (es)	2000-01-05
UY25079A1 (es)	2000-12-29
TW492960B (en)	2002-07-01
MA26519A1 (fr)	2004-12-20
AP9801291A0 (en)	1998-09-30
BG103992A (en)	2000-07-31
BR9810544A (pt)	2000-09-05
TNSN98127A1 (fr)	2005-03-15
CA2294193A1 (en)	1999-01-14

Publication	Publication Date	Title
OA11236A (en)	2003-05-27	Azetidinylpropylpiperidine derivatives intermediates and use as tachykinin antagonists
EP0862567B1 (en)	2001-08-01	5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists
NO311977B1 (no)	2002-02-25	(Azetidin-1-ylalkyl) laktamer som tachykinin-antagonister
EP0861251A1 (en)	1998-09-02	Morpholine derivatives and their use as therapeutic agents
JPH11501640A (ja)	1999-02-09	５−ｈｔ▲下４▼拮抗作用を有するジ−置換１，４−ピペリジンエステル類及びアミド類
US6242438B1 (en)	2001-06-05	3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
US5846965A (en)	1998-12-08	3-aza and 3-oxa piperidone tachykinin antagonists
US6022971A (en)	2000-02-08	Azetidines
HRP20030923A2 (en)	2004-02-29	Novel piperidinecarboxamide derivatives, method for prreparing same and pharmaceutical compositions containing same
EP1150970A1 (fr)	2001-11-07	Derives de (1-phenacy-3-phenyl-3-piperidylethyl)piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
MXPA99012092A (es)	2000-08-01	Azetidinas
CZ9904659A3 (cs)	2000-10-11	Azetidinylpropylpiperidinové deriváty, meziprodukty a jejich použití jako tachykininových antagonistů
HK1029585A (en)	2001-04-06	Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists